SAN FRANCISCO, May 1, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- MedImmune, Inc.
(Nasdaq: MEDI) has awarded six pediatric fellows a portion of a $210,000
pediatric research grant, in the amount of $35,000 each. The grants were
provided by MedImmune's Pediatric Fellowship Program, which is designed to
stimulate increased interest and research in the area of respiratory
pathogens. The six recipients were announced on Saturday, April 29 at a
reception coinciding with the annual meeting of the Pediatric Academic
Societies in San Francisco.
"This fellowship program supports and encourages researchers who are
continuously expanding their knowledge and understanding of potentially severe
pediatric infectious diseases such as respiratory syncytial virus (RSV) and
influenza," said Niki Oquist, M.D., senior director, medical affairs at
An independent advisory board consisting of 15 pediatric infectious
disease physicians from across the country selected the six fellowship
recipients. All candidates were required to be full-time fellows in an
American Board of Pediatrics-accredited fellowship program and conducting
original research as their primary focus.
"Selecting only six recipients out of the many talented and impressive
applicants was not an easy task," Dr. Oquist noted. "The pool of applicants
and their mentors were of the highest caliber which made the final selection
process very challenging. The company is honored to provide financial aid to
these researchers and their work."
The six recipients of the fellowship grants are: Alex Daneshmand, D.O.,
University of Florida; E. Kathryn Miller, M.D., Vanderbilt University Medical
Center; Deniz Kesebir, M.D., Yale University School of Medicine; Stacey
Peterson-Carmichael, M.D., University of North Carolina at Chapel Hill;
Cynthia Somers, M.D., University of Texas Southwestern Medical Center at
Dallas; Angela Peck, M.D., Seattle Children's Medical Center.
These grants may be used to help supplement fellowship salaries or
research project costs. MedImmune has funded the fellowship program for the
past three years. MedImmune's Pediatric Fellowship Program is one example of
the company's broader, ongoing commitment to research and pediatric health.
To date, MedImmune has invested more than $2 billion in research funds to
develop new and next-generation medicines against respiratory viruses such as
RSV and influenza.
About MedImmune, Inc.
MedImmune strives to provide better medicines to patients, new medical
options for physicians, rewarding careers to employees, and increased value to
shareholders. Dedicated to advancing science and medicine to help people live
better lives, the company is focused on the areas of infectious diseases,
cancer and inflammatory diseases. With more than 2,200 employees worldwide,
MedImmune is headquartered in Maryland. For more information, visit the
company's website at http://www.medimmune.com.
SOURCE MedImmune, Inc.
Media: Clarencia Stephen of MedImmune, Inc., +1-301-398-4073